Oxford Immunotec Signs Exclusive Distributor Agreement with RIKEN Genesis, a Subsidiary of Sysmex, to Market the T-SPOT® Discovery SARS-CoV-2 Kit for the Measurement of the T cell Immune Response to SARS-CoV-2 Infection in Japan
December 02, 2020 09:00 ET
|
Oxford Immunotec Global PLC
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announces...
Oxford Immunotec to Hold a Virtual Investor Event on December 17, 2020
November 23, 2020 07:30 ET
|
Oxford Immunotec Global PLC
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced...
Data Showing SARS-CoV-2 Reactive T Cells are Associated with Protection from COVID-19 – and Can Be Both Detected and Measured Using Oxford Immunotec’s T-SPOT® Technology – is Published by Public Health England and Oxford Immunotec
November 10, 2020 09:00 ET
|
Oxford Immunotec Global PLC
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today...
Oxford Immunotec Files Submission to Food and Drug Administration (FDA) for the T-Cell Select™ Reagent Kit
November 05, 2020 09:00 ET
|
Oxford Immunotec Global PLC
If approved, the T-Cell Select reagent kit would enable automated sample preparation and the T-SPOT®.TB test to be used with blood samples stored for up to 54 hours at room temperature OXFORD, United...
Oxford Immunotec Reports Third Quarter 2020 Financial Results
November 03, 2020 07:00 ET
|
Oxford Immunotec Global PLC
Third quarter revenue of $19.4 million, above guidance of range of $18 - $19 million Asia-Pacific region returns to growth and sets a new quarterly sales record for the regionEurope & rest of...
UK Vaccines Taskforce has Selected Oxford Immunotec as the Sole Supplier of T cell Testing for SARS-CoV-2 Specific Responses in New COVID Vaccine Trials
October 22, 2020 05:30 ET
|
Oxford Immunotec Global PLC
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today...
Oxford Immunotec Schedules Third Quarter 2020 Earnings Release and Conference Call for November 3, 2020
October 21, 2020 16:05 ET
|
Oxford Immunotec Global PLC
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced...
Oxford Immunotec Announces Food and Drug Administration (FDA) Clearance of the T-SPOT®.TB Test for Use in Pediatrics Over the Age of Two
September 29, 2020 09:00 ET
|
Oxford Immunotec Global PLC
OXFORD, United Kingdom and MARLBOROUGH, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today...
Oxford Immunotec Joins Forces with Public Health England (PHE) in a Large Clinical Trial Utilizing T-SPOT® Discovery™ SARS-CoV-2 Test
September 22, 2020 09:00 ET
|
Oxford Immunotec Global PLC
OXFORD, United Kingdom and MARLBOROUGH, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today...
Oxford Immunotec Reports Second Quarter 2020 Financial Results
August 04, 2020 07:00 ET
|
Oxford Immunotec Global PLC
Second quarter revenue of $5.8 million, a decrease of 70% compared to prior year period, due to the impact of COVID-19 Ended the quarter with approximately $165 million of cash and cash equivalents...